Q4 2024 Cencora Inc Earnings Call Transcript
Key Points
- Cencora Inc (COR) reported a 15% increase in adjusted earnings for fiscal 2024, demonstrating strong financial performance.
- The company has made significant investments in its core distribution infrastructure and strategic partnerships, enhancing its capabilities.
- Cencora's acquisition of Retina Consultants of America expands its community provider relationships in a high-growth segment.
- The company continues to benefit from strong customer relationships and a robust international footprint.
- Cencora has a strong focus on specialty pharmaceuticals, which are a key differentiator and growth driver for the company.
- Cencora took a $418 million goodwill impairment on its PharmaLex business due to lower-than-expected growth.
- The US healthcare solutions segment experienced pressure from increased sales of low-margin GLP-1 products.
- The international healthcare solutions segment saw a decline in operating income due to higher IT expenses and lower income in Canada.
- The company faces headwinds from COVID-related products, impacting its fiscal 2025 guidance.
- Cencora's PharmaLex business is facing broader demand challenges in the outsourced pharmacy services market.
Hello, everyone, and thank you for your patience. Today is Cencora's Q4 full-year 2024 earnings call, we'll begin shortly. (Operator Instructions)
Hello, everyone, and welcome to today's Cenciora Q4 full-year 2024 earnings call. My name is Drew, and I'll be the operator today. (Operator Instructions) I'll now hand over to our first speaker, Bennett Murphy. Please go ahead when you're ready.
Thank you. Good morning, good afternoon, thank you all for joining us on this conference call to discuss Cencora's fiscal 2024 fourth-quarter and full-year results. I am Bennett Murphy, Senior Vice President, Head of Investor Relations and Treasury. Joining me today are Bob Mauch, President and CEO; and Laz Krikorian, Senior Vice President and Chief Accounting Officer.
On today's call, we will be discussing non-GAAP financial measures. Reconciliations of these measures to GAAP are provided in today's press release, which is available on our website at investor.cencora.com. We have also
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
